NeoGenomics Q2 revenue $165M (+12% YoY); raises FY2024 EBITDA guidance to $33-37M

NEOGENOMICS INC

Q2 revenue $165M (+12% YoY); net loss narrowed 23% to $19M.
Adjusted EBITDA $11M (+630% YoY) vs -$2M in prior-year quarter.
Clinical Services revenue $141M (+15% YoY); Advanced Diagnostics $23M (-3%).
FY2024 guidance raised: revenue $655-667M (from $650-660M); adj. EBITDA $33-37M (from $21-24M).
Cash and marketable securities $388M at quarter end.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.